News on Mendelian diseases, hereditary cancer, variant classification, cystic fibrosis testing and more.
The service is the first of its kind in the UK and relies on the Illumina NovaSeq 6000 platform to deliver results.
Most of the disease risk carriers identified in the Healthy Nevada Project did not meet clinical guidelines for screening, according to the new analysis.
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.
The Rostock, Germany-based company reported €12.1 million ($13.6 million) in revenues, missing the average analyst estimate of $14.7 million.
The test has been developed to run on Illumina's NextSeq 550Dx next-generation sequencing platform and will be prepared for commercial launch in Europe.
